# US 2019/0319199 A1 · Organic electroluminescent materials and devices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0319199 A1
- Document ID: US20190319199A1
- Status: Published application
- Kind: A1
- Application number: 16/363,462
- Filed: 2019-03-25
- Published: 2019-10-17
- Earliest claimed: 2018-04-13
- Assignees: Universal Display Corporation
- Applicants: Universal Display Corporation
- Inventors: Scott Beers
- Web page: https://patentgrep.com/patent/US20190319199A1

## CPC

- C09K 11/06: containing organic luminescent materials
- C07F 15/0033: {Iridium compounds}
- C07F 15/0086: {Platinum compounds}
- H10K 85/342: {comprising iridium}
- C09K 2211/1044: containing two nitrogen atoms as heteroatoms
- C09K 2211/185: of the platinum group, i.e. Os, Ir, Pt, Ru, Rh or Pd
- H10K 50/11: characterised by the electroluminescent [EL] layers
- H10K 85/654: {comprising only nitrogen as heteroatom (H10K85/652 takes precedence)}
- H10K 85/6572: {comprising only nitrogen in the heteroaromatic polycondensed ring system, e.g. phenanthroline or carbazole}
- H10K 2101/10: Triplet emission
- C09K: MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- H10K: ORGANIC ELECTRIC SOLID-STATE DEVICES

## Abstract

A compound comprising a ligand LA of Formulae I, II, or III wherein the ligand LA is coordinated to a transition metal M, and optionally, M is also coordinated to a ligand LB; A is N, B, or CR7; Y is absent, or selected from the group consisting of C(O), C(Rya)(Ryb), C═C(Rya)(Ryb), and Si(Rya)(Ryb), where if Y of Ring A is absent then ring carbon of R2 is bonded to N; wherein for the compounds of formula III at least one of R2, R3, and R4 is selected from N(Ar1)RN′ or aryloxy; wherein Ar1 is selected from aryl or heteroaryl, each of which is optionally substituted. An OLED that includes an organic layer disposed between an anode and a cathode, and the organic layer includes a compound comprising a ligand LA of Formulae I, II, or III above. The OLED can be incorporated into one or more of a consumer product, e.g., an electronic component module, a flat panel display, e.g., a display for a phone, television, laptop, and/or a lighting panel for either commercial or residential applications.

## Claims

### Claim at position 1

-25. (canceled)

### Claim 26

A compound comprising a ligand LA of Formulae I, II, or III
wherein the ligand LA is coordinated to a metal M as represented by the dashed lines, and optionally, the metal M is coordinated to a ligand LB;
A is N, B, or CR7;
Y is absent, or selected from the group consisting of C(O), C(Rya)(Ryb), C═C(Rya)(Ryb), and Si(Rya)(Ryb), where if Y of Ring A is absent then ring carbon of R2 is bonded to N; wherein Rya and Ryb are independently hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, aryl, heteroaryl, and any combination thereof; or Rya and Ryb can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted;
R1, R2, R3, R4, R5, R6, and R7 are independently hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, phosphino, sulfanyl, sulfinyl, sulfonyl, and any combination thereof; or optionally, any two adjacent R4, R5, R6, and R7 can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted;
RN is selected from the group consisting of hydrogen, deuterium, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, aryl, heteroaryl, nitrile, and any combination thereof;
wherein for the compounds of formula I, the adjacent R2, R3, or R4, or R1 and RN, can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted;
wherein for the compounds of formula II, the adjacent R1, R2 or R3, or R4 and RN, can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted; and
wherein for the compounds of formula III at least one of R2, R3, and R4 is selected from N(Ar1)RN′ or aryloxy; wherein Ar1 is selected from aryl or heteroaryl, each of which is optionally substituted; and RN′ is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, aryl, and heteroaryl, each of which is optionally substituted; or Ar1 and RN′ can join to form a N-carbazoyl ring, which is optionally substituted; or optionally, the adjacent R1, R2, R3, or R4 can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted.

### Claim 27 (depends on 26)

The compound of claim 26, wherein R1, R2, R3, R4, R5, R6, and R7 are independently hydrogen or a substituent selected from the group consisting of deuterium, fluorine, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, nitrile, isonitrile, sulfanyl, and combinations thereof.

### Claim 28 (depends on 26)

The compound of claim 26, wherein A is N.

### Claim 29 (depends on 26)

The compound of claim 26, wherein A is CR7.

### Claim 30 (depends on 26)

The compound of claim 26, wherein Y is absent in the compounds of the formula I or the compounds of the formula II.

### Claim 31 (depends on 26)

The compound of claim 26, wherein R2, or optionally RN for the compounds of formulae I and II, are selected from the group consisting of:
a straight, or branched, alkyl of one to six carbons, which is optionally substituted with a group selected from deuterium, fluorine, aryl, heteroaryl, and combinations thereof;
an aryl, optionally substituted with a group selected from deuterium, fluorine, a straight, or branched, alkyl of one to six carbons, aryl, heteroaryl, and combinations thereof;
a heteroaryl, optionally substituted with a group selected from deuterium, fluorine, a straight, or branched, alkyl of one to six carbons, aryl, heteroaryl, and combinations thereof.

### Claim 32 (depends on 26)

The compound of claim 26, wherein the ligand LA is of formulae IV, V, or VI;
wherein R8 and R9 are independently hydrogen or a substituent selected from the group consisting of deuterium, halide, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, aryl, heteroaryl, and any combination thereof; or the adjacent R8 and R9 can join to form an aliphatic, aryl or heteroaryl ring, which is optionally substituted.

### Claim 33 (depends on 26)

The compound of claim 26 of a formula M(LA)x(LB)y; wherein the ligand LA and the ligand LB are each bidentate; x is 1, 2, or 3, and y is 0, 1, or 2, and x+y is the oxidation state of the metal; wherein each of the ligand LA, and the ligand LB, in the compound can be the same or different if x is 2 or 3, or y is 2, respectively.

### Claim 34 (depends on 26)

The compound of claim 26, wherein M is selected from Pt or Pd; wherein the coordination to the metal includes one or two ligand(s) LA of the formulae I, II, or III, the ligand LA linked to the same or different ligand LA, or the optional ligand LB, through R1 to form a tetradentate ligand.

### Claim 35 (depends on 26)

The compound of claim 26 selected from the group consisting of
LAx
R1
R2
R3
R4
R5
R6
RN
LA1
H
H
H
H
H
H
CH3
LA2
H
CH3
H
H
H
H
CH3
LA3
H
H
CH3
H
H
H
CH3
LA4
H
CH3
CH3
H
H
H
CD3
LA5
H
CH3
CH3
H
H
t-Bu
CH3
LA6
H
H
H
H
H
CH3
CH3
LA7
H
i-Pr
H
H
H
t-Bu
CH3
LA8
H
i-Pr
i-Pr
H
H
t-Bu
CD3
LA9
H
i-Pr
CH3
H
H
t-Bu
i-Pr
LA10
H
i-Bu
H
H
H
t-Bu
i-Pr
LA11
H
i-Bu
i-Bu
H
H
t-Bu
i-Bu
LA12
H
CH3
H
H
H
t-Bu
2,6-
CH3—Ph
LA13
H
CH3
CH3
H
H
t-Bu
2,6-
CH3—Ph
LA14
H
i-Pr
H
H
H
t-Bu
2,6-
CH3—Ph
LA15
H
i-Pr
i-Pr
H
H
t-Bu
2,6-
CH3—Ph
LA16
H
i-Bu
H
H
H
t-Bu
2,6-
CH3—Ph
LA17
H
i-Bu
i-Bu
H
H
t-Bu
2,6-
CH3—Ph
LA18
H
i-Pr
CH3
H
H
t-Bu
2,6-i-
Pr—Ph
LA19
H
i-Bu
CH3
H
H
t-Bu
2,6-i-
Pr—Ph
LA20
H
i-Bu
H
H
H
t-Bu
2,6-i-
Pr—Ph
LA21
H
i-Bu
i-Bu
H
H
t-Bu
2,6-i-
Pr—Ph
LA22
CH3
H
H
H
H
t-Bu
CH3
LA23
CH3
CH3
H
H
H
t-Bu
CH3
LA24
CH3
CH3
CH3
H
H
t-Bu
CH3
LA25
CH3
i-Pr
H
H
H
t-Bu
CH3
LA26
CH3
i-Pr
i-Pr
H
H
t-Bu
CH3
LA27
CH3
i-Bu
H
H
H
t-Bu
CH3
LA28
CH3
i-Bu
i-Bu
H
H
t-Bu
CD3
LA29
CH3
H
H
H
H
t-Bu
i-Bu
LA30
CH3
CH3
CH3
H
H
t-Bu
i-Bu
LA31
CH3
i-Bu
H
H
H
t-Bu
i-Bu
LA32
CH3
i-Bu
i-Bu
H
H
t-Bu
i-Bu
LA33
CH3
H
H
H
H
t-Bu
2,6-
CH3—Ph
LA34
CH3
CH3
H
H
H
t-Bu
2,6-
CH3—Ph
LA35
CH3
i-Bu
H
H
H
t-Bu
2,6-
CH3—Ph
LA36
CH3
i-Bu
CH3
H
H
t-Bu
2,6-
CH3—Ph
LA37
CH3
i-Bu
i-Bu
H
H
t-Bu
2,6-
CH3—Ph
LA38
CH3
H
H
H
H
t-Bu
2,6-
i-Pr—Ph
LA39
CH3
CH3
H
H
H
t-Bu
2,6-
i-Pr—Ph
LA40
CH3
i-Pr
CH3
H
H
t-Bu
2,6-
i-Pr—Ph
LA41
CH3
i-Bu
CH3
H
H
t-Bu
2,6-
i-Pr—Ph
LA42
CH3
i-Bu
i-Bu
H
H
t-Bu
2,6-
i-Pr—Ph
LA43
CH3
i-Bu
i-Bu
H
H
CD3
2,6-
i-Pr—Ph
LA44
CH3
i-Bu
H
H
H
CD3
2,6-
i-Pr—Ph
LA45
CH3
i-Bu
CH3
H
H
CD3
2,6-
i-Pr—Ph
LA46
H
H
H
H
H
2,6-CH3—Ph
CH3
LA47
H
i-Bu
CH3
H
H
2,6-CH3—Ph
i-Bu
LA48
H
i-Bu
i-Bu
H
H
2,6-CH3—Ph
i-Pr
LA49
H
i-Pr
CH3
H
H
2,6-CH3—Ph
i-Bu
LA50
H
i-Bu
H
H
H
2,6-CH3—Ph
2,6-
CH3—Ph
LA51
H
i-Bu
H
H
H
2,6-iPr—Ph
CH3
LA52
H
i-Bu
CH3
H
H
2,6-iPr—Ph
i-Bu
LA53
H
i-Bu
i-Bu
H
H
2,6-iPr—Ph
2,6-
CH3—Ph
LA54
CH3
H
H
H
H
2,6-CH3—Ph
CH3
LA55
CH3
i-Bu
H
H
H
2,6-CH3—Ph
i-Pr
LA56
CH3
i-Bu
CH3
H
H
2,6-CH3—Ph
i-Bu
LA57
CH3
i-Bu
i-Bu
H
H
2,6-CH3—Ph
2,6-
CH3—Ph
LA58
CH3
i-Bu
i-Bu
H
H
2,6-i-Pr—Ph
CH3
LA59
CH3
i-Bu
i-Bu
H
H
2,6-i-Pr—Ph
i-Pr
LA60
CD3
i-Bu
i-Bu
H
H
2,6-i-Pr—Ph
2,6-
CH3—Ph
LA61
CD3
i-Pr
CH3
H
H
2,6-i-Pr—Ph
2,6-
CH3—Ph;
LAx
R1
R2
R3
R4
R5
R6
RN
LA62
H
H
H
H
H
H
CH3
LA63
H
CH3
H
H
H
H
CH3
LA64
H
CH3
CH3
H
H
H
CH3
LA65
H
i-Bu
CH3
H
H
CH3
CH3
LA66
H
i-Bu
H
H
H
CH3
CH3
LA67
H
i-Bu
i-Bu
H
H
CD3
CH3
LA68
H
i-Bu
CH3
H
H
t-Bu
CD3
LA69
H
H
H
H
H
t-Bu
CH3
LA70
H
CH3
H
H
H
t-Bu
CH3
LA71
H
CH3
CH3
H
H
t-Bu
CH3
LA72
H
i-Bu
H
H
H
t-Bu
i-Bu
LA73
H
i-Bu
CH3
H
H
t-Bu
i-Bu
LA74
H
i-Bu
i-Bu
H
H
t-Bu
i-Bu
LA75
H
i-Bu
i-Bu
H
H
t-Bu
2,6-
CH3—Ph
LA76
H
H
H
H
H
t-Bu
2,6-
CH3—Ph
LA77
H
CH3
H
H
H
t-Bu
2,6-
CH3—Ph
LA78
H
CH3
CH3
H
H
t-Bu
2,6-
CH3—Ph
LA79
H
i-Bu
H
H
H
t-Bu
2,6-
CH3—Ph
LA80
H
i-Bu
CH3
H
H
t-Bu
2,6-
CH3—Ph
LA81
H
i-Bu
i-Bu
H
H
t-Bu
2,6-
CH3—Ph
LA82
H
i-Bu
i-Bu
H
H
t-Bu
2,6-
i-Pr—Ph
LA83
H
H
H
H
H
2,6-CH3—Ph
CH3
LA84
H
CH3
H
H
H
2,6-CH3—Ph
CD3
LA85
H
i-Bu
H
H
H
2,6-CH3—Ph
i-Bu
LA86
H
i-Bu
CH3
H
H
2,6-CH3—Ph
i-Bu
LA87
H
i-Bu
i-Bu
H
H
2,6-CH3—Ph
2,6-
CH3—Ph
LA88
H
H
H
H
H
2,6-CH3—Ph
2,6-
CH3—Ph
LA89
H
i-Bu
CH3
H
H
2,6-CH3—Ph
2,6-
CH3—Ph
LA90
H
i-Bu
i-Bu
H
H
2,6-i-Pr—Ph
2,6-
CH3—Ph
LA91
H
i-Bu
CH3
H
H
2,6-i-Pr—Ph
CD3
LA92
H
i-Bu
i-Bu
H
H
2,6-i-Pr—Ph
i-Bu
LA93
H
i-Pr
CH3
H
H
2,6-i-Pr—Ph
i-Pr
LA94
H
i-Pr
i-Pr
H
H
2,6-i-Pr—Ph
2,6-
i-Pr—Ph
LA95
CH3
H
H
H
H
H
CH3
LA96
CH3
CH3
H
H
H
CH3
CH3
LA97
CH3
CH3
CH3
H
H
t-Bu
CH3
LA98
CH3
i-Bu
H
H
H
t-Bu
CD3
LA99
CH3
i-Bu
i-Bu
H
H
t-Bu
i-Pr
LA100
CH3
i-Bu
CH3
H
H
t-Bu
i-Bu
LA101
CH3
i-Bu
i-Bu
H
H
t-Bu
i-Pr
LA102
CH3
i-Bu
i-Bu
H
H
t-Bu
2,6-
CH3—Ph
LA103
CH3
i-Bu
i-Pr
H
H
t-Bu
2,6-
CH3—Ph
LA104
CH3
i-Bu
CH3
H
H
t-Bu
2,6-
CH3—Ph
LA105
CD3
i-Bu
CH3
H
H
t-Bu
2,6-
CH3—Ph
LA106
CD3
i-Bu
i-Bu
H
H
2,6-CH3—Ph
i-Pr
LA107
CD3
i-Bu
i-Bu
H
H
2,6-CH3—Ph
i-Bu
LA108
CD3
i-Pr
i-Pr
H
H
2,6-CH3—Ph
2,6-
CH3—Ph
LA109
CD3
i-Bu
i-Bu
H
H
2,6-i-Pr—Ph
2,6-
CH3—Ph
LA110
CH3
i-Bu
i-Bu
H
H
2,6-i-Pr—Ph
CH3
LA111
CH3
i-Bu
H
H
H
2,6-i-Pr—Ph
i-Pr
LA112
CH3
i-Bu
CH3
H
H
2,6-i-Pr—Ph
i-Bu
LA113
CH3
i-Bu
i-Bu
H
H
2,6-i-Pr—Ph
2,6-
i-Pr—Ph;
LAx
Ar1
RN
R1
R2
R6
LA114
2,6-CH3—Ph
Ph
H
H
H
LA115
2,6-CH3—Ph
Ph
H
H
CH3
LA116
2,6-CH3—Ph
Ph
H
H
CD3
LA117
2,6-CH3—Ph
Ph
H
H
t-Bu
LA118
2,6-CH3—Ph
Ph
H
H
2,6-
CH3—Ph
LA119
2,6-CH3—Ph
Ph
H
H
2,6-
i-Pr—Ph
LA120
2,6-CH3—Ph
Ph
H
CH3
H
LA121
2,6-CH3—Ph
Ph
H
CH3
CH3
LA122
2,6-CH3—Ph
Ph
H
CH3
t-Bu
LA124
2,6-CH3—Ph
Ph
H
CH3
2,6-
i-Pr—Ph
LA125
2,6-CH3—Ph
2-CH3—Ph
H
H
CH3
LA126
2,6-CH3—Ph
2-CH3—Ph
H
H
CD3
LA127
2,6-CH3—Ph
2-CH3—Ph
H
H
t-Bu
LA128
2,6-CH3—Ph
2-CH3—Ph
H
H
2,6-
CH3—Ph
LA129
2,6-CH3—Ph
2-CH3—Ph
H
H
2,6-
i-Pr—Ph
LA130
2,6-CH3—Ph
2-CH3—Ph
H
CH3
CH3
LA131
2,6-CH3—Ph
2-CH3—Ph
H
CH3
CD3
LA132
2,6-CH3—Ph
2-CH3—Ph
H
CH3
t-Bu
LA133
2,6-CH3—Ph
2-CH3—Ph
H
CH3
2,6-
CH3—Ph
LA134
2,6-CH3—Ph
2-CH3—Ph
H
CH3
2,6-
i-Pr—Ph
LA135
2,6-CH3—Ph
2-CH3—Ph
CH3
H
CH3
LA136
2,6-CH3—Ph
2-CH3—Ph
CH3
H
CD3
LA137
2,6-CH3—Ph
2-CH3—Ph
CH3
H
t-Bu
LA138
2,6-CH3—Ph
2-CH3—Ph
CH3
H
2,6-
CH3—Ph
LA139
2,6-CH3—Ph
2-CH3—Ph
CH3
H
2,6-
i-Pr—Ph
LA140
2,6-CH3—Ph
Ph
CH3
H
CH3
LA141
2,6-CH3—Ph
Ph
CH3
H
CD3
LA142
2,6-CH3—Ph
Ph
CH3
H
t-Bu
LA143
2,6-CH3—Ph
Ph
CH3
H
2,6-
CH3—Ph
LA144
2,6-CH3—Ph
Ph
CH3
H
2,6-
i-Pr—Ph
LA145
2-i-Pr—Ph
2-i-Pr—Ph
CH3
H
CH3
LA146
2-i-Pr—Ph
2-i-Pr—Ph
CH3
H
t-Bu
LA147
2-i-Pr—Ph
2-i-Pr—Ph
CH3
H
2,6-
CH3—Ph
LA148
2-i-Pr—Ph
2-i-Pr—Ph
CH3
H
2,6-
i-Pr—Ph
LA149
2-i-Pr—Ph
2-i-Pr—Ph
H
CH3
CH3
LA150
2-i-Pr—Ph
2-i-Pr—Ph
H
CH3
t-Bu
LA151
2-i-Pr—Ph
2-i-Pr—Ph
H
CH3
2,6-
CH3—Ph
LA152
2-i-Pr—Ph
2-i-Pr—Ph
H
CH3
2,6-
i-Pr—Ph
LA153
2-i-Pr—Ph
2-i-Pr—Ph
CH3
CH3
t-Bu
LA154
2-i-Pr—Ph
2-i-Pr—Ph
CH3
CH3
2,6-
CH3—Ph
LA155
2-i-Pr—Ph
2-i-Pr—Ph
CH3
CH3
2,6-
i-Pr—Ph
LA156
2,6-i-Pr—Ph
Ph
CH3
CH3
t-Bu
LA157
2,6-i-Pr—Ph
Ph
CH3
H
2,6-
CH3—Ph
LA158
2,6-i-Pr—Ph
Ph
H
H
2,6-
i-Pr—Ph
LA159
2-CH3—Ph
2-CH3—Ph
H
H
t-Bu
LA160
2-CH3—Ph
2-CH3—Ph
CH3
CH3
t-Bu
LA161
2-CH3—Ph
2-CH3—Ph
H
CH3
2,6-
CH3—Ph
LA162
2-CH3—Ph
2-CH3—Ph
H
CH3
2,6-
i-Pr—Ph
LA163
2,6-CH3—Ph
2,6-CH3—Ph
H
CH3
t-Bu
LA164
2,6-CH3—Ph
2,6-CH3—Ph
H
CH3
2,6-
CH3—Ph
LA165
2,6-CH3—Ph
2,6-CH3—Ph
H
CH3
2,6-
i-Pr—Ph
LA166
2,6-CH3—Ph
2,6-CH3—Ph
H
H
t-Bu
LA167
2,6-CH3—Ph
2,6-CH3—Ph
H
H
2,6-
CH3—Ph
LA168
2,6-CH3—Ph
2,6-CH3—Ph
H
H
2,6-
i-Pr—Ph.

### Claim 36 (depends on 26)

The compound of claim 26, wherein the ligand LB is present and is independently selected from the group consisting of:
wherein the dashed lines represent coordination to the metal M;
X1 to X13 are independently selected from the group consisting of C and N;
X is selected from the group consisting of BR′, NR′, PR′, O, S, Se, C═O, S═O, SO2, CR′R″, SiR′R″, and GeR′R″;
R′ and R″ are optionally fused or joined to form an aliphatic, aryl or heteroaryl ring;
Ra, Rb, Rc, and Rd may represent from mono substitution to the possible maximum number of substitution, or no substitution;
R′, R″, Ra, Rb, Rc, and Rd are independently hydrogen or a substituent selected from the group consisting of deuterium, halide, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, nitrile, isonitrile, phosphino, carbonyl, sulfanyl, and any combination of substituents thereof; or any two adjacent Ra, Rb, Re, and Rd can join to form an aliphatic, aryl or heteroaryl ring, which is optionally substituted.

### Claim 37 (depends on 36)

The compound of claim 36, wherein the ligand LB is present and is independently selected from the group consisting of;

### Claim 38 (depends on 35)

The compound of claim 35, wherein the compound is the Compound Ax having the formula Ir(LAi)3, or the Compound By having the formula Ir(LAi)(LBk)2;
wherein x=i, and y=468+k−468;
wherein i is an integer from 1 to 168, and k is an integer from 1 to 468;
wherein each LBk has the following structure:

### Claim 39

An organic light emitting device (OLED) comprising:
an anode; a cathode; and an organic layer, disposed between the anode and the cathode, the organic layer including a compound comprising a ligand LA of Formulae I, II, or III:
wherein the ligand LA is coordinated to a transition metal M as represented by the dashed lines, and optionally, the metal M is coordinated to a ligand LB;
A is N, B, or CR7;
Y is absent, or selected from the group consisting of C(O), C(Rya)(Ryb), C═C(Rya)(Ryb), and Si(Rya)(Ryb), where if Y of Ring A is absent then ring carbon of R2 is bonded to N; wherein Rya and Ryb are independently hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, aryl, heteroaryl, and any combination thereof, or Rya and Ryb can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted;
R1, R2, and R3 are independently hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, phosphino, sulfanyl, sulfinyl, sulfonyl, and any combination thereof;
RN is selected from the group consisting of hydrogen, deuterium, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, aryl, heteroaryl, nitrile, and any combination thereof;
wherein for the compounds of formula III at least one of R2, R3, and R4 is selected from N(Ar1)RN′ or aryloxy; wherein Ar1 is selected from aryl or heteroaryl, each of which is optionally substituted; and RN′ is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, aryl, and heteroaryl, each of which is optionally substituted; or Ar1 and RN′ can join to form a N-carbazoyl ring, which is optionally substituted; and
R4, R5, R6, and R7 are independently hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, phosphino, sulfanyl, sulfinyl, sulfonyl, and any combination thereof; or any two adjacent R4, R5, R6, and R7 can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted;
wherein for the compounds of formula I, the adjacent R2, R3, and R4, or R1 and RN, can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted;
wherein for the compounds of formula II, the adjacent R1, R2 and R3, and/or R4 and RN can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted; and
wherein for the compounds of formula III, the adjacent R1, R2, R3, and R4 can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted.

### Claim 40 (depends on 39)

The OLED of claim 39 wherein the organic layer further comprises a host, wherein the host comprises at least one chemical group selected from the group consisting of triphenylene, carbazole, dibenzothiphene, dibenzofuran, dibenzoselenophene, azatriphenylene, azacarbazole, aza-dibenzothiophene, aza-dibenzofuran, and aza-dibenzoselenophene.

### Claim 41 (depends on 39)

The OLED of claim 39, wherein the host is selected from the group consisting of;
and combinations thereof.

### Claim 42

A consumer product that includes an organic light-emitting device (OLED), the OLED including an anode, a cathode, and an organic layer disposed between the anode and the cathode, the organic layer including a compound comprising a ligand LA Of Formulae I, II, or III:
wherein the ligand LA is coordinated to a transition metal M as represented by the dashed lines, and optionally, the metal M is coordinated to a ligand LB;
A is N, B, or CR7;
Y is absent, or selected from the group consisting of C(O), C(Rya)(Ryb), C═C(Rya)(Ryb), and Si(Rya)(Ryb), where if Y of Ring A is absent then ring carbon of R2 is bonded to N; wherein Rya and Ryb are independently hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, aryl, heteroaryl, and any combination thereof, or Rya and Ryb can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted;
R1, R2, and R3 are independently hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, phosphino, sulfanyl, sulfinyl, sulfonyl, and any combination thereof,
RN is selected from the group consisting of hydrogen, deuterium, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, aryl, heteroaryl, nitrile, and any combination thereof,
wherein for the compounds of formula III at least one of R2, R3, and R4 is selected from N(Ar1)RN′ or aryloxy; wherein Ar1 is selected from aryl or heteroaryl, each of which is optionally substituted; and RN′ is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, aryl, and heteroaryl, each of which is optionally substituted; or Ar1 and RN′ can join to form a N-carbazoyl ring, which is optionally substituted; and
R4, R5, R6, and R7 are independently hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, phosphino, sulfanyl, sulfinyl, sulfonyl, and any combination thereof, or any two adjacent R4, R5, R6, and R7 can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted;
wherein for the compounds of formula I, the adjacent R2, R3, and R4, or R1 and RN, can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted;
wherein for the compounds of formula II, the adjacent R1, R2 and R3, and/or R4 and RN can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted; and
wherein for the compounds of formula III, the adjacent R1, R2, R3, and R4 can join to form a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted.

### Claim 43 (depends on 42)

The consumer product of claim 42, wherein the consumer product is selected from the group consisting of a flat panel display, a computer monitor, a medical monitor, a television, a billboard, a light for interior or exterior illumination and/or signaling, a heads-up display, a fully or partially transparent display, a flexible display, a laser printer, a telephone, a cell phone, tablet, a phablet, a personal digital assistant (PDA), a wearable device, a laptop computer, a digital camera, a camcorder, a viewfinder, a micro-display that is less than 2 inches diagonal, a 3-D display, a virtual reality or augmented reality display, a vehicle, a video walls comprising multiple displays tiled together, a theater or stadium screen, a light therapy device, and a sign.

### Claim 44 (depends on 26)

A formulation comprising a compound of claim 26.
